Reaction
Nasal Septum Perforation reporting signals
As of the last recalculation, Nasal Septum Perforation appears in 639 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is BEVACIZUMAB (PRR 32.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bevacizumab | 105 | 32.8 | 32.9 |
| Irinotecan Hydrochloride | 10 | 25.7 | 25.7 |
| Esketamine Hydrochloride | 5 | 9.2 | 9.2 |
| Cabozantinib | 13 | 9.0 | 9.0 |